Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease | Heart
MEDVASC - VOYAGER : le rivaroxaban 2,5 mg X 2, c'est oui
Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD | SpringerLink
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition with XARELTO Plus Aspirin in Patients with Coronary Artery Disease, Peripheral Artery Disease | DAIC
Study design of COMPASS. To assess the safety and efficacy of... | Download Scientific Diagram
COMPASS | Xarelto Global
The COMPASS Trial | Circulation
COMPASS study of rivaroxaban to end early for efficacy - Cardiovascular News
Épisode 10 : Étude COMPASS - BaladoCritique : Club de lecture médical - Université de Sherbrooke
The COMPASS Trial | Circulation
Le Rivaroxaban (Xarelto®): état des lieux des nouvelles données et perspectives thérapeutiques | Louvain Médical
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease | NEJM
Eikelboom Net Clinical Benefit Video | XARELTO® (rivaroxaban)
Peripheral Artery Disease, the Factor Xa Inhibitor Rivaroxaban, and the Role of the Podiatrist
COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease | tctmd.com
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System | SpringerLink
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios | Current Cardiology Reports
COMPASS - Research Studies - PHRI - Population Health Research Institute of Canada
Xarelto® (Rivaroxaban) - COMPASS-studien - Xarelto i kombination med ASA vid kranskärlsjukdom
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin - ScienceDirect
Study design of COMPASS. To assess the safety and efficacy of... | Download Scientific Diagram
Figure 2, COMPASS Design Schematic - Clinical Review Report: Rivaroxaban ( Xarelto) - NCBI Bookshelf
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial - The Lancet
